MOZOBIL 20 MG
PLERIXAFOR : 20 MG · DIN 02377225 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is MOZOBIL?
MOZOBIL 20 MG contains PLERIXAFOR : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02377225, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 31-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MOZOBIL used for?
In combination with G-CSF to mobilize hematopoietic stem cells for autologous transplantation in patients with non-Hodgkin’s lymphoma, multiple myeloma, or pediatric solid malignant tumors.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02377225 |
|---|---|
| Brand name | MOZOBIL |
| Generic / active ingredient | PLERIXAFOR : 20 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L03AX16 PLERIXAFOR |
| AHFS class | 20:16.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Oct-2025 |
| Original market date | 2012-03-26 00:00:00 |
How is it administered?
Administered SC 10-11 hours prior to apheresis after 4 days of G-CSF. Adult dose: 20 mg fixed or 0.24 mg/kg (max 40 mg/day). Pediatric: 0.24 mg/kg.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (standard storage section 11 was listed in TOC but text ends before it).
How is it supplied?
Single-use 2.0 mL clear glass (Type I) vial, filled to deliver 1.2 mL of 20 mg/mL solution.
Contraindications
Hypersensitivity to plerixafor or to any ingredient in the formulation or component of the container.
Warnings and precautions
Potential for tumor cell mobilization in leukemia; risk of splenic enlargement/rupture; leukocytosis; thrombocytopenia; vasovagal reactions; allergic reactions including anaphylaxis.
What can be used instead?
Other Canadian products sharing ATC code L03AX16 PLERIXAFOR. 2 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PLERIXAFOR INJECTION | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02529815 |
| PLERIXAFOR INJECTION | 20 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02539454 |
| PLERIXAFOR INJECTION | 20 MG | SOLUTION | FRESENIUS KABI CANADA LTD | APPROVED | DIN 02490846 |
Who else supplies PLERIXAFOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PLERIXAFOR appears in 35 registered pack listings across 10 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.